INVESCO LTD (IVZ) Stock Fundamental Analysis
NYSE:IVZ - New York Stock Exchange, Inc. - BMG491BT1088 - Common Stock - Currency: USD
IVZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 222 industry peers in the Capital Markets industry. IVZ may be in some trouble as it scores bad on both profitability and health. IVZ is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IVZ was profitable.
IVZ had a positive operating cash flow in the past year.
IVZ had positive earnings in 4 of the past 5 years.
IVZ had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
IVZ has a worse Return On Assets (-1.50%) than 82.95% of its industry peers.
The Return On Equity of IVZ (-2.80%) is worse than 79.72% of its industry peers.
IVZ's Return On Invested Capital of 2.06% is on the low side compared to the rest of the industry. IVZ is outperformed by 65.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.5% | ||
| ROE | -2.8% | ||
| ROIC | 2.06% |
ROA(3y)1.05%
ROA(5y)1.77%
ROE(3y)1.97%
ROE(5y)3.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IVZ's Profit Margin has been stable in the last couple of years.
IVZ has a worse Operating Margin (11.78%) than 69.59% of its industry peers.
In the last couple of years the Operating Margin of IVZ has declined.
With a decent Gross Margin value of 66.74%, IVZ is doing good in the industry, outperforming 66.36% of the companies in the same industry.
IVZ's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.78% | ||
| PM (TTM) | N/A | ||
| GM | 66.74% |
OM growth 3Y-18.12%
OM growth 5Y-10.75%
PM growth 3Y-24%
PM growth 5Y-0.8%
GM growth 3Y-1.08%
GM growth 5Y-0.72%
2. Health
2.1 Basic Checks
Compared to 1 year ago, IVZ has less shares outstanding
The number of shares outstanding for IVZ has been reduced compared to 5 years ago.
Compared to 1 year ago, IVZ has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.02, we must say that IVZ is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.02, IVZ is in line with its industry, outperforming 52.53% of the companies in the same industry.
The Debt to FCF ratio of IVZ is 5.07, which is a neutral value as it means it would take IVZ, 5.07 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of IVZ (5.07) is comparable to the rest of the industry.
IVZ has a Debt/Equity ratio of 0.51. This is a neutral value indicating IVZ is somewhat dependend on debt financing.
The Debt to Equity ratio of IVZ (0.51) is better than 70.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 1.02 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
IVZ has a Current Ratio of 0.75. This is a bad value and indicates that IVZ is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.75, IVZ is doing worse than 63.13% of the companies in the same industry.
A Quick Ratio of 0.75 indicates that IVZ may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.75, IVZ is doing worse than 62.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.75 | ||
| Quick Ratio | 0.75 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.91% over the past year.
IVZ shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.57% yearly.
The Revenue has been growing slightly by 6.13% in the past year.
Measured over the past years, IVZ shows a decrease in Revenue. The Revenue has been decreasing by -0.17% on average per year.
EPS 1Y (TTM)13.91%
EPS 3Y-17.74%
EPS 5Y-7.57%
EPS Q2Q%10.64%
Revenue 1Y (TTM)6.13%
Revenue growth 3Y-4.17%
Revenue growth 5Y-0.17%
Sales Q2Q%10.64%
3.2 Future
The Earnings Per Share is expected to grow by 6.74% on average over the next years.
IVZ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.54% yearly.
EPS Next Y8.2%
EPS Next 2Y9.64%
EPS Next 3Y10.22%
EPS Next 5Y6.74%
Revenue Next Year6.21%
Revenue Next 2Y5.54%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 11.19, the valuation of IVZ can be described as reasonable.
Based on the Price/Earnings ratio, IVZ is valued a bit cheaper than 66.82% of the companies in the same industry.
When comparing the Price/Earnings ratio of IVZ to the average of the S&P500 Index (28.28), we can say IVZ is valued rather cheaply.
A Price/Forward Earnings ratio of 10.35 indicates a reasonable valuation of IVZ.
68.20% of the companies in the same industry are more expensive than IVZ, based on the Price/Forward Earnings ratio.
IVZ's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 91.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.19 | ||
| Fwd PE | 10.35 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IVZ is valued a bit cheaper than 73.27% of the companies in the same industry.
IVZ's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IVZ is cheaper than 81.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.88 | ||
| EV/EBITDA | 17.07 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.37
PEG (5Y)N/A
EPS Next 2Y9.64%
EPS Next 3Y10.22%
5. Dividend
5.1 Amount
IVZ has a Yearly Dividend Yield of 4.24%, which is a nice return.
IVZ's Dividend Yield is comparable with the industry average which is at 9.43.
IVZ's Dividend Yield is rather good when compared to the S&P500 average which is at 2.27.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.24% |
5.2 History
The dividend of IVZ has a limited annual growth rate of 1.50%.
IVZ has been paying a dividend for at least 10 years, so it has a reliable track record.
IVZ has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.5%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
IVZ has negative earnings and hence a negative payout ratio. The dividend may be in danger.
The dividend of IVZ is growing, but earnings are growing more, so the dividend growth is sustainable.
DP-146.45%
EPS Next 2Y9.64%
EPS Next 3Y10.22%
INVESCO LTD
NYSE:IVZ (1/30/2025, 12:03:05 PM)
19.255
+0.25 (+1.34%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners89.71%
Inst Owner Change-0.5%
Ins Owners0.68%
Ins Owner Change0.32%
Market Cap8.65B
Analysts66.67
Price Target18.76 (-2.57%)
Short Float %2.73%
Short Ratio3.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.24% |
Yearly Dividend1.32
Dividend Growth(5Y)1.5%
DP-146.45%
Div Incr Years3
Div Non Decr Years3
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.75%
Min EPS beat(2)1.96%
Max EPS beat(2)7.53%
EPS beat(4)3
Avg EPS beat(4)1.89%
Min EPS beat(4)-18.24%
Max EPS beat(4)16.32%
EPS beat(8)5
Avg EPS beat(8)-0.93%
EPS beat(12)6
Avg EPS beat(12)-4.14%
EPS beat(16)10
Avg EPS beat(16)-0.14%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-1.29%
Max Revenue beat(2)-1.23%
Revenue beat(4)0
Avg Revenue beat(4)-3.47%
Min Revenue beat(4)-7.11%
Max Revenue beat(4)-1.23%
Revenue beat(8)2
Avg Revenue beat(8)5.23%
Revenue beat(12)6
Avg Revenue beat(12)12.47%
Revenue beat(16)10
Avg Revenue beat(16)17.91%
PT rev (1m)-0.35%
PT rev (3m)4.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.41%
EPS NY rev (1m)0%
EPS NY rev (3m)3.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.09%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)0.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.19 | ||
| Fwd PE | 10.35 | ||
| P/S | 1.47 | ||
| P/FCF | 5.88 | ||
| P/OCF | 5.45 | ||
| P/B | 0.59 | ||
| P/tB | 41.77 | ||
| EV/EBITDA | 17.07 |
EPS(TTM)1.72
EY8.93%
EPS(NY)1.86
Fwd EY9.67%
FCF(TTM)3.27
FCFY17%
OCF(TTM)3.53
OCFY18.34%
SpS13.1
BVpS32.83
TBVpS0.46
PEG (NY)1.37
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.5% | ||
| ROE | -2.8% | ||
| ROCE | 2.76% | ||
| ROIC | 2.06% | ||
| ROICexc | 2.15% | ||
| ROICexgc | 6.67% | ||
| OM | 11.78% | ||
| PM (TTM) | N/A | ||
| GM | 66.74% | ||
| FCFM | 24.99% |
ROA(3y)1.05%
ROA(5y)1.77%
ROE(3y)1.97%
ROE(5y)3.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-18.12%
OM growth 5Y-10.75%
PM growth 3Y-24%
PM growth 5Y-0.8%
GM growth 3Y-1.08%
GM growth 5Y-0.72%
F-Score5
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 8.51 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 181.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.75 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | 1.02 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.91%
EPS 3Y-17.74%
EPS 5Y-7.57%
EPS Q2Q%10.64%
EPS Next Y8.2%
EPS Next 2Y9.64%
EPS Next 3Y10.22%
EPS Next 5Y6.74%
Revenue 1Y (TTM)6.13%
Revenue growth 3Y-4.17%
Revenue growth 5Y-0.17%
Sales Q2Q%10.64%
Revenue Next Year6.21%
Revenue Next 2Y5.54%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.13%
EBIT growth 3Y-21.53%
EBIT growth 5Y-10.89%
EBIT Next Year19.68%
EBIT Next 3Y10.74%
EBIT Next 5Y3.3%
FCF growth 1Y72.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.18%
OCF growth 3YN/A
OCF growth 5YN/A